Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04554667
Other study ID # 20-0169
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 24, 2020
Est. completion date July 31, 2022

Study information

Verified date September 2022
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LIFTING trial will examine the feasibility and safety of a heavy lifting strength training (HLST) program in head and neck cancer survivors (HNCS) at least 1 years post surgical neck dissection. The trial will determine whether this training style is safe and feasible in HNCS. Physical and psychosocial changes will also be reported.


Description:

RATIONALE Despite improvements in treatments, HNCS still endure numerous acute and chronic side effects. Strength training has been shown to manage some of these side effects but most interventions have involved light-to-moderate resistance training programs. HLST may produce better outcomes but it is unknown if such a weight training program is feasible and safe for HNCS. OBJECTIVE The primary aim of this proposed study is to examine the feasibility and safety of a HLST program in HNCS at least 1 year post-surgical neck dissection. METHODS This single arm feasibility study will recruit 15-20 HNCS to complete the HLST program 2 times per week. The primary feasibility outcomes will include the eligibility rate (with reasons for ineligibility), recruitment rate (with reasons for refusal), 1 repetition maximum testing rate (with reasons for not completing the test), program adherence (including attendance, dose modifications, and progression), and follow-up assessment rate (with reasons for drop out). The primary efficacy outcome will be strength gains from baseline. Secondary efficacy outcomes will include physical functioning, quality of life, fear of cancer recurrence, pain, body composition, anxiety, fatigue, stress, shoulder mobility, self-esteem, sleep, and motivation to engage in a HLST program. SIGNIFICANCE Weight training is an effective intervention in HNCS but the optimal weight training prescription is unknown. If heavy weight training is deemed safe and feasible in HNCS, it can be compared to light-to-moderate load weight training to determine if it is a better prescription for improving outcomes that are important to HNCS.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date July 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - previously diagnosed with any subtype and stage of head and neck cancer - at least one year post surgical neck dissection for head and neck cancer and showing full shoulder range of motion or recovery of the spinal accessory nerve - adults ages 18 and older - no unmanaged medical conditions, alcohol, and drug abuse - approved for a heavy lifting strength training program by the treating surgeon and a certified exercise physiologist - ability to understand and communicate in English Exclusion Criteria: - having comorbidities or uncontrolled medical conditions that their referred clinicians indicate as inappropriate to participate in exercise

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise Intervention
Heavy Lifting Strength Training

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment Rate Recruitment rate (with reasons for refusal).
Recruitment minimum: 15 participants Recruitment maximum: 20 participants Higher number= better and more data
Over 12 weeks
Primary Muscular Strength Change in muscular strength from baseline to postintervention with be assessed using maximal strength tests.
Minimum: none Maximum: none Higher score= better strength
Changes from baseline to 12 weeks
Primary Program Adherence Program adherence minimum: 80% Program adherence maximum: 100% Higher score= better adherence Over 12 weeks
Secondary Physical functioning Assessed using the Neck Dissection Impairment Index (NDII) and maximum strength tests.
Minimum: 40 Maximum: 100 Higher score= worse impairment
Changes from baseline to 12 weeks
Secondary Fear of cancer recurrence Assessed using the Fear of Cancer Recurrence Inventory (FCRI)
Minimum: 0 Maximum: 36 Higher score= worse fear of cancer recurrence
Changes from baseline to 12 weeks
Secondary Post Traumatic Growth after cancer How cancer has changed an individual's life will be assessed using the Post Traumatic Growth Inventory (PTGI)
Minimum: 0 Maximum: 105 Higher score= better (positive) post traumatic growth transformation
Changes from baseline to 12 weeks
Secondary Waist to hip ratio (body composition) Assessed using waist to hip ratio (WHR) measure.
Minimum WHR: none Maximum WHR: none Higher score WHR= worse body composition
Changes from baseline to 12 weeks
Secondary Anxiety Assessed using the Spielberger State Trait Anxiety Inventory (STAI)
Minimum: 20 Maximum: 80 Higher score= worse anxiety
Changes from baseline to 12 weeks
Secondary Fatigue Assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire
Minimum: 0 Maximum: 52 Higher score=worse fatigue
Changes from baseline to 12 weeks
Secondary Stress Assessed using the Perceived Stress Scale (PSS)
Minimum: 0 Maximum: 56 Higher score=worse perceived stress
Changes from baseline to 12 weeks
Secondary Shoulder Mobility Changes in shoulder mobility
Minimum: 150 degrees (18-50 years); 130 degrees (over 50 years) Maximum: none Higher score= better mobility
Changes from baseline to 12 weeks
Secondary Self-Esteem Changes in level of self-esteem assessed using Rosenberg Self-Esteem (RSE) scale
Minimum: 10 Maximum: 40 Higher score= better self-esteem
Changes from baseline to 12 weeks
Secondary Sleep Changes in sleep patterns assessed using the insomnia severity index (ISI)
Minimum: 0 Maximum: 28 Higher score= worse insomnia
Changes from baseline to 12 weeks
Secondary Motivation Questions based on the theory of planned behaviour
Minimum: 7 Maximum: 35 Higher score= better motivation
Changes from baseline to 12 weeks
Secondary Cancer specific quality of life Assessed using the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N Symptom Index)
Minimum: 0 Maximum: 40 Higher score= worse head and neck cancer symptoms
Changes from baseline to 12 weeks
Secondary Cancer Symptom Burden Assessed using the revised Edmonton Symptom Assessment System (ESAS-r)
Minimum: 0 Maximum: 100 Higher score= worse cancer symptoms
Changes from baseline to 12 weeks
Secondary Height Assessed using standing height without shoes.
Minimum height: none Maximum height: none Taller: not specifically better or worse
Changes from baseline to 12 weeks
Secondary Weight Assessed using a digital scale without shoes.
Minimum weight: none Maximum weight: none Higher weight: typically worse, but depends on other factors (ie. height, muscle mass, overall health status)
Changes from baseline to 12 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT05331131 - Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial Phase 2
Completed NCT05269342 - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer N/A
Completed NCT03574870 - Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer N/A
Recruiting NCT04804852 - Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
Active, not recruiting NCT04617678 - A Comprehensive Approach to Head and Neck Cancer Prehabilitation N/A
Completed NCT03419741 - Brain Stimulation For Cancer Smokers N/A
Recruiting NCT02528955 - De-Intensification Radiotherapy Postoperative Head Neck Phase 2
Completed NCT00318890 - Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT05316974 - Lymphoedema Among Persons With Head- and Neck Cancer
Not yet recruiting NCT03954691 - Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
Active, not recruiting NCT03760471 - Palliative and Oncology Care Intervention: Symptom COACH N/A
Completed NCT02869399 - Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention N/A
Completed NCT02366611 - Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer N/A
Completed NCT02075112 - Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck Phase 1
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT02900911 - Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy N/A
Completed NCT01317589 - Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective? Phase 4
Completed NCT03841175 - Forecasts Impact of the Pre-therapeutic TEP-TDM in the 18-FDG Restaging of Upper Aero-digestive Tract Cancers
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2